Outreach and
Ambulatory Labs
Cost pressures, new payment models, technological innovations and evolving consumer preferences are transforming the health sector and causing health systems to evaluate their portfolio.
While labs account for a small fraction of system costs, they are often evaluated for their cost-effectiveness and efficiency. We can help you conduct a thorough evaluation of your lab operations, so you can better assess in-house versus a partnership or divestiture.
Evaluate the strategic value of your outreach or ambulatory lab business.
Some health systems have invested the capital, human resources, operations infrastructure, IT platforms and financial systems to run robust inreach or outreach labs; however, serving the ambulatory market requires significant investment and expertise beyond operating a clinical lab. We can work with you to evaluate how your ambulatory lab fits into your portfolio strategically.
Develop a partnership to enhance patient services and increase operational efficiency.
- Multiple investment options including outreach divestiture
- Integrated logistics, collections and processing provide enhanced services and reduced operating costs
- Comprehensive services through our nearly 5,000 test menu with access to new and advanced diagnostics
- Network utilization portal and population health tools
- Improved provider connectivity and workflow
- Expanded patient access and support tools
News
Labcorp announces a laboratory relationship with Ascension.
In February 2022, we entered into an agreement* for a comprehensive, strategic relationship with Ascension to manage their hospital-based labs in 10 states and to purchase select assets of the health system's outreach lab business.
Adam Schechter, chairman and CEO of Labcorp, notes that “by connecting two mission-driven organizations delivering high-quality service and care, we can provide care teams with the information and tools needed to make the best possible decisions to improve patient outcomes.”
When complete, this relationship will provide Ascension with enhanced opportunities for physicians and patients, including access to clinical trials, innovative new therapies and, where appropriate, new treatment options.
*Transaction is subject to customary closing conditions and is expected to close in the first half on 2022.